PA1151XC

OriGene Technologies Inc.

9620 Medical Center Drive, Ste 200
Rockville, MD 20850
UNITED STATES
Phone: +1-858-888-7900
Fax: +1-858-888-7904
US-info@acris-antibodies.com

OriGene EU

Acris Antibodies GmbH
Schillerstr. 5
32052 Herford
GERMANY
Phone: +49-5221-34606-0
Fax: +49-5221-34606-11
info@acris-antibodies.com

Recombinant Human I-309 (CCL1)

Alternate names: CCL1, I309, TCA3

Catalog No.: PA1151XC

Quantity: 1 mg

Concentration: 1 mg/ml

Species: Human

Source: E. coli, E.coli

Format:
State: Sterile Filtered White lyophilized (freeze-dried) powder.
Purity: >99% Greater than 99.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained.
Buffer System: Human I-309 was lyophilized from a concentrated sterile solution containing no additives.
Endotoxin Level: Less than 0.1 ng/µg (IEU/µg) of Human HCC-1.
Dimers: Less than 1% as determined by silver-stained SDS-PAGE gel analysis.
Reconstitution: It is recommended to reconstitute the lyophilized Human I-309 in sterile 18MO-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.

Description:
Recombinant Human I-309 produced in E.Coli is a single,non-glycosylated, polypeptide chain containing 74 amino acids. Human I-309 is purified by proprietary chromatographic techniques.
AA Sequence:
`The sequence of the first five N-terminal amino acids was determined and was found to be Ser-Lys-Ser-Met-Gln.`
Biological Activity: Human I-309 is fully biologically active when compared to standard. The Biological activity is calculated by its ability to chemoattract human T cells at 10.0-100.0 ng/ml.
Molecular weight: 8504 Dalton.
Molecular weight: 9 kDa

Add. Information:
Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280 nm .
2. Analysis by RP-HPLC, using a calibrated solution of Human I-309 as a Reference Standard.

Storage:
Lyophilized I-309 although stable at room temperature for 3 weeks, should be stored desiccated below -18 C. Upon reconstitution Human I-309 should be stored at 4 C between 2-7 days and for future use below -18 C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.

General Readings:

1. Gilchrest H, Cheewatrakoolpong B, Billah M, Egan RW, Anthes JC, Greenfeder S. Human cord blood-derived mast cells synthesize and release I-309 in response to IgE. Life Sci. 2003 Oct 3;73(20):2571-81. PubMed PMID: 12967681.
2. Louahed J, Struyf S, Demoulin JB, Parmentier M, Van Snick J, Van Damme J, et al. CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I. Eur J Immunol. 2003 Feb;33(2):494-501. PubMed PMID: 12645948.
3. Ruckes T, Saul D, Van Snick J, Hermine O, Grassmann R. Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309. Blood. 2001 Aug 15;98(4):1150-9. PubMed PMID: 11493464.
4. Inngjerdingen M, Damaj B, Maghazachi AA. Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309. J Immunol. 2000 Apr 15;164(8):4048-54. PubMed PMID: 10754297.
5. Haque NS, Fallon JT, Taubman MB, Harpel PC. The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium. Blood. 2001 Jan 1;97(1):39-45. PubMed PMID: 11133740.
6. Bernardini G, Spinetti G, Ribatti D, Camarda G, Morbidelli L, Ziche M, et al. I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo. Blood. 2000 Dec 15;96(13):4039-45. PubMed PMID: 11110671.

Pictures: PA1151XCME0607